anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PRIMARY OBJECTIVES: I. To determine the optimal tolerated dose of Doxil when given in combination with daily oral cyclophosphamide in patients with stage IV breast cancer. (Phase I) II. To determine the efficacy (overall clinical response rate) of the optimal tolerated dose of Doxil when given in combination with daily oral cyclophosphamide and herceptin (for HER2 neu positive patients) in patients with stage IV breast cancer. (Phase II) SECONDARY OBJECTIVES: I. To assess the treatment related toxicity associated with each dose level of this regimen and assess efficacy (overall clinical response rate). (Phase I) II. To assess the safety (treatment related toxicity) of the optimal tolerated dose of Doxil when given in combination with daily oral cyclophosphamide and herceptin (for HER2 neu positive patients) in patients with stage IV breast cancer. (Phase II) III. To assess time to progression and overall survival following treatment with Doxil and daily oral cyclophosphamide and herceptin (for HER2 neu positive patients). (Phase II) IV. To compare the response rate in patients who are heavily pretreated to the response rate in patients who are less heavily pretreated. OUTLINE: This is a phase I, dose-escalation study of pegylated doxorubicin HCl liposome followed by a phase II feasibility study. Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Persistent pulmonary hypertension of newborn (PPHN) is a serious condition that results from failure of the normal postnatal circulatory transition and is associated with significant mortality and morbidity. Advanced medical treatment, such as inhaled nitric oxide (iNO), high-frequency ventilation (HFV), and extracorporeal membrane oxygenation (ECMO) are commonly not available in developing countries. Intravenous magnesium sulfate has been shown to alleviate pulmonary hypertension but is associated with systemic hypotension and is less effective compared with iNO and sildenafil. Nebulized magnesium sulfate has been reported to be more effective and safer compared with intravenous magnesium sulfate in treating neonates with PPHN on mechanical ventilation. Combined nebulized magnesium and sildenafil has been studied in a small trial on spontaneously breathing neonates with PPHN but not on those connected to mechanical ventilation.

The aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate combined with sildenafil citrate, compared with sildenafil citrate alone, in treating neonates with severe PPHN on mechanical ventilation. We hypothesize that neonates with severe PPHN connected to mechanical ventilation could benefit from taking continuous nebulization of magnesium sulfate combined besides sildenafil.
Loss of the ability to walk is one of the significant problems in persons with multiple sclerosis (MS). This limitation prevents the person from having an active and meaningful life at home and in the community. Also, more energy is needed to walk, which can cause fatigue and further leads to a non-active life style and poor quality of life. Unfortunately, walking training is often not available for this population because of the severity and progress of the disease; therefore, a new strategy is needed to help people with MS to walk again. A new technology, the wearable robotic exoskeleton, has been developed to help persons with spinal cord injuries stand up and walk. The robotic legs are powered by batteries and controlled by motors. This study will investigate the use of a wearable robotic exoskeleton to help persons with MS to walk. Participants will receive trainings (5 days per week for 3 weeks) to walk with the robotic exoskeleton (EKSO, EKSO Bionics, Richmond, CA). During the training, a physical therapist will teach the participant how to maintain balance, sit to stand, stand to sit, and walk with the wearable robotic exoskeleton. The hypothesis is that persons with MS will be able to use a robotic exoskeleton to walk better and with less energy costs.
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide. Although CRC patients' survival is improved with surgical resection and immunotherapy, metastasis and recurrence remain major problems leading to poor prognosis. Therefore, exploring pathogenesis and identifying specific biomarkers are crucial for CRC early diagnosis and targeted therapy. CCDC113, a member of CCDC families, has been reported to play roles in ciliary assembly, ciliary activity, PSCI, asthma and early lung cancer diagnosis. However, the functions of CCDC113 in CRC still remain unclear. In this study, we find that CCDC113 is significantly highly expressed in CRC. High expression of CCDC113 is significantly correlated with CRC patients' poor prognosis. CCDC113 is required for CRC tumorigenesis and metastasis. RNA-seq and TCGA database analysis indicate that CCDC113 is positively correlated with TGF-β signaling pathway. TGF-β signaling pathway inhibitor galunisertib could reverse the increased proliferation and migration ability of CRC cells caused by CCDC113 overexpression in vitro and in vivo. These results indicate that CCDC113 promotes CRC tumorigenesis and metastasis via TGF-β signaling pathway. In conclusion, it is the first time to explore the functions and mechanisms of CCDC113 in CRC tumorigenesis and metastasis. And CCDC113 may be a potential biomarker and therapeutic target for CRC intervention.
The present invention relates to a verbena herb extract which is prepared from traditional Chinese medicine verbena herb extracted by alcohol. An ethanol extracting solution is concentrated. Water is added, and petroleum ether is used for extracting solution of petroleum ether is discarded, and a water layer is extracted by chloroform. A verbena herb extract is obtained by distilling extractum obtained by a chloroform extraction liquid. The present invention discloses a preparation method of the verbena herb extract. The verbena herb extract of the present invention can be applied to preparing medicine against early pregnancy and nutritive layer cell tumors.
The invention relates to the technical field of a traditional Chinese medicine. The purpose of the invention is to provide a traditional Chinese medicine composition aiming at pulmonary tuberculosis according to the knowledge mechanism of pulmonary tuberculosis in traditional Chinese medicine. The traditional Chinese medicine composition comprises the following raw materials, according to a weight part ratio, 20-40 parts of blighted wheat, 20-40 parts of raw oysters, 7-11 parts of Chinese angelica, 7-11 parts of ephedra roots, 10-20 parts of raw milkvetch roots, and 10-20 parts of unprocessed rehmannia roots. The traditional Chinese medicine composition is decocted with water, the medicine liquid is administered twice a day, and the course of treatment is six days. The traditional Chinese medicine is available in raw materials and good in curative effect, and has no side effect. The traditional Chinese medicine is taken by hundreds of patients who suffer from pulmonary tuberculosis, and according to the statistics, the effective rate can reach more than 95.5%.
Coronary angiography is an essential diagnostic tool for determining the presence and severity of coronary artery disease, a leading cause of morbidity and mortality worldwide. While the basic techniques of coronary angiography have remained unchanged, the field of medical imaging has undergone significant advancements in hardware and software, offering new possibilities for enhanced visualization of the coronary arteries, better diagnostic accuracy, and improved patient and staff safety. However, the use of radiation during coronary angiography, which is necessary for image acquisition, exposes patients, physicians, and staff to potential risks, including radiation-induced tissue damage and an increased long-term risk of cancer. While the risks to patients attributable to the relatively low radiation doses they receive during single catheterization procedures are minimal, the cumulative risks of occupational radiation exposure are higher among physicians and staff, who are repetitively exposed to scattered radiation on a daily basis and accumulated over the course of years working in the catheterization laboratory. This occupational radiation exposure has been associated with an increased risk of cataracts, premature atherosclerosis, and certain cancers among physicians and staff. There is therefore a pressing need to explore strategies to minimize radiation doses used during coronary angiography without compromising the diagnostic accuracy of coronary artery disease detection.

Recent advancements in computational power and image processing algorithms provide opportunities for substantial reductions in radiation doses used during coronary angiography. One such advancement is spatiotemporal enhancement processing (STEP) which improves the signal to noise ratio of time sequenced angiographic data and enhances the visibility of vascular structure. This innovative STEP technique has the promise of minimizing patient and operator radiation exposure while maintaining adequate image quality. The purpose of this pilot study is to investigate a novel strategy of radiation dose reduction and data processing in coronary angiography. This pilot study will be performed in patients undergoing clinically-indicated diagnostic coronary angiography.

The study will compare angiograms acquired at ultralow radiation doses and processed with spatiotemporal enhancement software (STEP-angiograms) to standard of care angiograms (SOC-angiograms) acquired with normal radiation dose settings and no additional processing. The objectives are to assess offline whether the low radiation STEP-angiograms are of equivalent diagnostic quality as SOC-angiograms. In future research studies, the STEP software will be tested in the clinical setting to evaluate how the software may improve patient safety, enhance the overall quality of care, promote the responsible use of radiation in coronary angiography procedures, and reduce occupational radiation doses among physician and staff in the catheterization laboratory.
Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. In six-month phase 1 study, the participants in Control-Intervention group maintained usual care for diabetes. During the second half six-month phase 2 study, they received tailored mobile coaching.
ABSTRACT OF THE DISCLOSURE            A method is disclosed for producing hybridoma cell lines by fusion of immunized splenocytes of the mouse with mouse myeloma cells.  The splenocytes are immunized against interleukin-6 prior to the fusion.  Three different cell ines can be identified and isolated from the fused cells, that is the hybridoma cell line with the C.N.C.M. deposition number I/913 (BE-8), the hybridoma cell line with the C.N.C.M. depositon number I/911 (BE-4) and the hybridoma cell line with the C.N.C.M. deposition number I/912 (BF-6), which produce monoclonal antibodies which recognize human interleukin-6 and which in dependence upon the different cell lines each bind themselves to a different epitope on the interleukin-6 molecule.
The invention relates to the pharmaceutical and biotechnology industry for wound healing and organ re-epithelisation treatments. The advantages of the invention with respect to compositions of the prior art are that, in addition to accelerating the healing process, the composition makes it possible to speed up organ re-epithelisation without generating hyperplasia, thereby improving organ quality following a deterioration. The composition is formed by a growth factor and a neuropeptide. The growth factor is epidermal growth factor, while the neuropeptide is neurotensin. The composition contains epidermal growth factor in a concentration of 0.00001-10 mg/ml and neurotensin in a concentration of 0.00001-10 mg/ml. The combination can have any pharmaceutical form and can be administered by any route of administration.
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. There is no nomogram model available for mortality prediction of stable COPD. We intended to develop and validate a nomogram model to predict mortality risk in stable COPD patients for personalised prognostic assessment.
METHODS: A prospective observational study was made of COPD outpatients registered in the RealDTC study between December 2016 and December 2019. Patients were randomly assigned to the training cohort and validation cohort in a ratio of 7:3. We used Lasso regression to screen predicted variables. Further, we evaluated the prognostic performance using the area under the time-dependent receiver operating characteristic curve (AUC) and calibration curve. We used the AUC, concordance index, and decision curve analysis to evaluate the net benefits and utility of the nomogram compared with three earlier prediction models.
RESULTS: Of 2499 patients, the median follow-up was 38 months. The characteristics of the patients between the training cohort (n = 1743) and the validation cohort (n = 756) were similar. ABEODS nomogram model, combining age, body mass index, educational level, airflow obstruction, dyspnoea, and severe exacerbation in the first year, was constructed to predict mortality in stable COPD patients. In the integrative analysis of training and validation cohorts of the nomogram model, the three-year mortality prediction achieved AUC = 0.84; 95% confidence interval (CI) = 0.81, 0.88 and AUC = 0.80; 95% CI = 0.74, 0.86, respectively. The ABEODS nomogram model preserved excellent calibration in both the training cohort and validation cohort. The time-dependent AUC, concordance index, and net benefit of the nomogram model were higher than those of BODEx, updated ADO, and DOSE, respectively.
CONCLUSIONS: We developed and validated a prognostic nomogram model that accurately predicts mortality across the COPD severity spectrum. The proposed ABEODS nomogram model performed better than earlier models, including BODEx, updated ADO, and DOSE in Chinese patients with COPD.
REGISTRATION: ChiCTR-POC-17010431.
PROBLEM TO BE SOLVED: To provide a vanilla flavor which is excellent in taste, especially in substantiality, body, etc., by extracting a vanilla bean material with cacao butter. SOLUTION: Preferably, a vanilla bean material crushed so as to contain at least 50 wt.% particles having particle sizes of 10 mesh or lower based on the total particles is used. The preaddition of an emulsifier to cacao butter gives a vanilla flavor enhanced in strength of taste, substantiality, body, etc. The emulsifier, though not specifically limited, is exemplified by a sucrose fatty acid ester, and the amount of it used is preferably 0.01-10 pts.wt. based on 100 pts.wt. cacao butter. Though not specifically limited, the extraction of a vanilla bean material with cacao butter is conducted preferably at 40-130 deg.C for 30 min to 10 hr by agitation extraction. Thus obtained flavor can be added in an amount of 0.1-5 wt.% based on the total amount of fragrance- and flavor- imparting agents.
The invention relates to the field of biomedicine, in particular to a serum type 4 avian adenovirus strain, a vaccine composition, a multi-vaccine and application thereof. The serum type 4 avian adenovirus strain of the invention has the preservation number as follows: CGMCC No. 45070. The Hexon gene sequence of the strain is shown as SEQ ID NO. 1. The invention also relates to a vaccine, a vaccine composition and a concatenated vaccine prepared by using the strain. The strain has high pathogenicity, the lethality rate to 21-day-old SPF (specific pathogen free) chickens reaches 100%, and vaccines and vaccine compositions prepared from the strain have good immune protection.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to pharmaceutical composition used for prophylaxis and treatment of tumors associated with human papilloma viruses, namely, uterus cervix dysplasia and cancer and larynx papillomatosis. Invention proposes composition based on indole-3-carbinol as active component and methods of prophylaxis and treatment based on thereof. Invention provides another mechanism of inhibition of tumor growth with indole-3-carbinol being applicable for uterus cervix and larynx tumor cells. EFFECT: improved method of prophylaxis and treatment, valuable antitumor properties. 5 cl, 2 dwg, 6 ex
INTRODUCTION: Post infectious glomerulonephritis remains the most common cause leading to the majority of hospital admissions in children of developing countries like ours. The aim of our study was to find the prevalence of post infectious glomerulonephritis, study the clinical profile, biochemical changes and its complication in children admitted in a tertiary care hospital of Nepal.
METHODS: This descriptive cross-sectional study of children admitted at a tertiary care hospital was done from May 2020 till May 2023. A census sampling method was used and sample of 1554 children was taken. Detailed socio demographic data, clinical findings and laboratory investigations were done. Data analysis was done using SPSS software and the results obtained are shown in the form of frequencies along with percentages.
RESULTS: Among 1554 patients, the prevalence of acute post-infectious glomerulonephritis was found to be 63 (4.05%) (3.07-5.03 at 95% Confidence Interval). The mean age of the patients was 9.06±3.48 years. Antistreptolysin O titer was raised in 34 (54%) patients, while low serum C3 was observed in 39 (61.90%) patients with acute post-infectious glomerulonephritis.
CONCLUSIONS: Acute post-infectious glomerulonephritis (APIGN) remains a notable health concern in children, particularly in developing countries like Nepal. This highlights the need for ongoing surveillance, prevention strategies, and effective management protocols to address this burden effectively.
The present invention discloses composite oral liquid for treating dysentery of lambs and a preparing method thereof. The oral liquid comprises preventing agent and therapeutical agent, and is mainly used for treating the lamb dysentery of three-week old lambs. The main components of the oral liquid are sodium selenite, vitamin C, mequindox, pilose asiabell root, snow lotus herb and artemisiae scopariae. The preparing method comprises: dissolving the western medicines, and mixing the dissolved western medicines with the supernatant fluid of the Chinese medicines to prepare the oral liquid. The present invention is developed on the basis that the bodies of the lambs are lack of selenium. Each neonatal lamb can eat 10 ml of the preventing agent for one time after eating colostrum, and preventing rate can reach 100%. For the treatment of most of the livestock with lamb dysentery, only 10 ml of the therapeutical agent needs to be eaten, and a small number of the livestock can be cured after eating the therapeutical agent for two times.
BACKGROUND: The incidence of hip fractures is increasing. Femoral intertrochanteric fractures make up 50% of hip fractures and are treated by intramedullary nails. Implant breakage is a recognized complication that can have rare and serious implications. This study aimed to investigate implant breakage rates after surgical treatment for femoral intertrochanteric fractures.
METHODS: This was a retrospective multicenter analysis. All 1854 patients who underwent surgical treatment for femoral intertrochanteric fractures were selected from 12 hospitals (TRON group) between 2016 and 2020. Exclusion criteria included implants other than those specified and follow-up periods less than three months. Demographic data, surgical details, and radiographic assessments were collected from medical records and X-ray evaluations.
RESULTS: Among the 983 study patients, consisting of 245 males (24.9%) and 738 females (75.1%), the implant breakage rate was 0.31%, with three confirmed cases. The average age was 83.9 years. The mean follow-up period was 640.9 days. Two cases were linked to ASULOCK implants, and one to an OLSII implant. Statistical analysis showed a significantly higher incidence of ASULOCK implant breakage (p < 0.001). In the two cases of ASULOCK implant breakage and one case of OLSII implant breakage, breakage in all three implants occurred at the anti-rotation screws.
CONCLUSIONS: There were no implant breakages of the main body of the implants; all breakages occurred in the additional anti-rotation screw. The necessity of the anti-rotation screw will require further discussion. These results can potentially inform clinical decisions and guide further research in preventing implant breakage.
Usual care control group will meet once a month for educational lectures on various topics. At the end of 6 months, each control group participant will get a one-on-one session with the physical therapist who was leading the intervention classes.
To assess the performance of Biovance, patients will consulted regarding the history and previous treatment of their keloid. Once patients are deemed to be appropriate candidates, they will be enrolled in the study. Operatively, the old scar will be completely excised. Then the Biovance will be laid in the base of the wound. After this is performed, extensive undermining will be done to close the wound in layers.

All post-revision complications (including infection, incision dehiscence, hematoma, seroma, and wound necrosis) will be assessed and recorded by the investigator. Patients will be reviewed to obtain demographic and risk factor (such as age, body mass index, smoking) data. Data on adjuvant therapy use (previous surgeries, treatments for keloid scar) will be collected. Surgical technique details (such as incision size and closure technique) will also be recorded for each patient. Photographs documenting the pre-, intra- and post-revision clinical course of patients will be collected.
The pharmacological activity of oxcarbazepine (OXC) is primarily exerted through its active 10-monohydroxy metabolite (MHD). Nonetheless, there is limited pharmacokinetic information available regarding paediatric patients with epilepsy treated with OXC, especially in infants and toddlers. Concurrently, this drug exhibits substantial variability in pharmacokinetics and therapeutic response across different individuals. We aimed to develop a model to quantitatively investigate factors that affect MHD pharmacokinetics to formulate a dosage guideline for OXC in Chinese paediatric patients. A total of 297 MHD trough concentrations were obtained from 287 epileptic children. Six body weight (BW)-based allometric models were used for population pharmacokinetic modelling, while investigating the impact of other covariates on the apparent clearance. The one-compartment model and age cut-off model for the apparent clearance (CL/F) were established to describe the pharmacokinetics of MHD. The probability to obtain target trough concentration ranges (TTCRs) of MHD between 3 and 35 mg/L was determined by Monte Carlo simulations for doses ranging from 8 to 90 mg/kg/day. A new dose optimization strategy combining the dosage guidelines and Bayesian method provides a tailored approach for Chinese paediatric epileptic patients based on their individual BW and desired TTCRs of MHD, and also supports current dose recommendations, with the exception of children weighing ≤5 kg.